MedTrace Logo

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

NCT02970981 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-04-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and tolerability of treatment with Nivolumab in combination with Ipilimumab in subjects with resected Stages IIIB/IIIC/ IV melanoma.

Conditions

Interventions

BIOLOGICAL

Nivolumab

BIOLOGICAL

Ipilimumab

Sponsors & Collaborators

Principal Investigators

  • Jeffrey S Weber, MD, PhD · NYU Perlmutter Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-29
Primary Completion
2018-11-30
Completion
2022-05-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02970981 on ClinicalTrials.gov